Clinical Trial: NCT02855203
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Peter MacCallum Cancer Centre, Australia |
| Information Provided By: | Peter MacCallum Cancer Centre, Australia |
| Last Update Posted: | 2023-08-03 |
Study Overview
Brief Summary
This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body radiotherapy (SABR) for oligometastatic renal cell carcinoma (RCC). The investigators hypothesise that the safety profile of this combination will be clinically acceptable.
Official Title
Conditions
Intervention / Treatment
- Radiation: Stereotactic Ablative Body Radiosurgery (SABR)
- Drug: Pembrolizumab
Other Study ID Numbers
- 15/143
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Peter MacCallum Cancer Centre, Australia |
| Information Provided By: | Peter MacCallum Cancer Centre, Australia |
| Last Update Posted: | 2023-08-03 |
Study Overview
Brief Summary
This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body radiotherapy (SABR) for oligometastatic renal cell carcinoma (RCC). The investigators hypothesise that the safety profile of this combination will be clinically acceptable.
Official Title
Conditions
Intervention / Treatment
- Radiation: Stereotactic Ablative Body Radiosurgery (SABR)
- Drug: Pembrolizumab
Other Study ID Numbers
- 15/143